Back

SMAD4 MH2 Mutations Disrupt CREBBP/EP300 Recruitment and TGF-β-Induced Transcription in Colorectal Cancer

Islam, M. S.; Nizamuddin, S.; Haw Chan, T. E.; Fotouhi, O.; Koidl, S.; Timmers, H. T. M.

2026-07-09 cancer biology
10.64898/2026.06.30.735541 bioRxiv
Show abstract

SMAD4 is a central transcriptional effector of the TGF-{beta} signaling pathway and a frequently inactivated tumor suppressor gene in various cancers. Missense mutations in its MH2 domain are among the most prevalent somatic alterations in colorectal cancer (CRC). These mutations are associated with disease progression and poor prognosis, yet their precise mechanistic consequences have remained incompletely characterized. Here, we show that CRC-derived SMAD4 MH2 hotspot mutations (D351H, S357P, R361C, and R361H) selectively impair co-activator recruitment without disrupting chromatin occupancy. RNA-seq profiling demonstrated broad suppression of TGF-{beta} target gene expression across all mutants. Notably, the mutations confer distinct degrees of TGF-{beta} pathway unresponsiveness: R361H is completely refractory to TGF-{beta} stimulation, whereas R361C and S357P retain partial transcriptional responsiveness suggesting allele-specific differences in the severity of co-activator interface disruption. Genome-wide chromatin binding analysis by greenCUT&RUN confirmed that all mutants maintain wild-type-like genomic occupancy, as expected given that the MH1 DNA-binding domain is intact in each case. Proximity-dependent biotinylation mass spectrometry in COLO205 cells revealed that all four mutants exhibit markedly reduced interactions with the CREBBP/EP300 histone acetyltransferase complex and BRD4 relative to wild-type SMAD4 identifying disrupted co-activator engagement. Collectively, our findings establish that SMAD4 MH2 mutations impair TGF-{beta}-induced transcription by selectively reducing CREBBP/EP300 recruitment, which provides a molecular mechanism for the loss-of-function SMAD4 phenotype in CRC. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=154 SRC="FIGDIR/small/735541v1_ufig1.gif" ALT="Figure 1000"> View larger version (24K): org.highwire.dtl.DTLVardef@14f542eorg.highwire.dtl.DTLVardef@11fd220org.highwire.dtl.DTLVardef@1c3aa1org.highwire.dtl.DTLVardef@14d5a8e_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Oncogene
85 papers in training set
Top 0.2%
8.8%
2
Cell Reports
1498 papers in training set
Top 5%
6.6%
3
eLife
5828 papers in training set
Top 17%
6.6%
4
Nature Communications
5641 papers in training set
Top 29%
5.1%
5
Science Signaling
65 papers in training set
Top 0.1%
4.8%
6
PLOS Genetics
862 papers in training set
Top 3%
4.3%
7
NAR Cancer
37 papers in training set
Top 0.1%
4.0%
8
Molecular Cancer Research
49 papers in training set
Top 0.3%
3.2%
9
Scientific Reports
3612 papers in training set
Top 39%
2.7%
10
Nucleic Acids Research
1281 papers in training set
Top 7%
2.6%
11
Cancer Research
130 papers in training set
Top 1%
2.6%
50% of probability mass above
12
British Journal of Cancer
49 papers in training set
Top 0.6%
2.4%
13
Cell Communication and Signaling
51 papers in training set
Top 0.4%
2.1%
14
PLOS ONE
5266 papers in training set
Top 46%
1.9%
15
BMC Cancer
67 papers in training set
Top 1%
1.7%
16
International Journal of Molecular Sciences
494 papers in training set
Top 8%
1.7%
17
Clinical Epigenetics
60 papers in training set
Top 0.3%
1.7%
18
Journal of Biological Chemistry
690 papers in training set
Top 6%
1.7%
19
Cancers
213 papers in training set
Top 3%
1.7%
20
Molecular and Cellular Biology
47 papers in training set
Top 0.5%
1.5%
21
Clinical Cancer Research
64 papers in training set
Top 1%
1.3%
22
Cell Death Discovery
58 papers in training set
Top 0.8%
1.3%
23
Cell Death & Disease
21 papers in training set
Top 0.3%
1.3%
24
Genome Medicine
183 papers in training set
Top 4%
1.1%
25
Redox Biology
70 papers in training set
Top 1.0%
1.1%
26
Life Science Alliance
285 papers in training set
Top 6%
1.0%
27
Cellular and Molecular Gastroenterology and Hepatology
46 papers in training set
Top 0.8%
1.0%
28
Molecular Cancer
16 papers in training set
Top 0.3%
1.0%
29
Journal of Molecular Biology
232 papers in training set
Top 3%
1.0%
30
Cell Death & Disease
126 papers in training set
Top 3%
1.0%